ECTRIMS eLearning

Frequency of Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients in Turkey and Affecting Factors
ECTRIMS Learn. Ozakbas S. 10/27/17; 200541; P886
Serkan Ozakbas
Serkan Ozakbas
Contributions
Abstract

Abstract: P886

Type: Poster

Abstract Category: Clinical aspects of MS - 5 Epidemiology

Cognitive impairment (CI) is present in 40%-65% of the people with multiple sclerosis (pwMS) and this affects their quality of life. This cross-sectional multicentre study aimed to evaluate the frequency of CI in Turkey for the first time in relapsing-remitting MS patients. Moreover, factors affecting the presence of CI were also evaluated.
Patients between 18 and 55 years of age diagnosed with relapsing-remitting MS according to the 2005 McDonald criteria were included. Number of patients included from 12 geographical regions of Turkey was determined according to the population data of the Turkish Statistical Institute. Patients who had neurological disorders other than MS, those with a previous head trauma, alcohol/drug dependence or mental retardation, and pregnant/lactating women were excluded. MS-related CI was assessed using the Brief Repeatable Neuropsychological Battery (BRB-N), which includes 5 subtests: the Selective Reminding Test to assess verbal memory; the 10/36 Spatial Recall Test (10/36) to assess visual memory; the Symbol Digit Modalities Test to assess attention, visual precision search, and executive functions; the Paced Auditory Serial Addition Task 3 seconds to assess the maintenance of attention; and the Word List Generation to assess associative verbal fluency.
The analysis included 487 MS patients and 245 healthy controls. The cut-off value for CI was determined as -1SD (standard deviation) of the mean value in at least 2 subtests of the BRB-N test of the healthy subjects. Accordingly, the frequency of CI in the MS patients was found as 53.7% (n=248). Comparison of the characteristics of the MS patients with and without CI revealed that those with CI were older (37.32±9.31 vs. 32.08±8.46 years; p< 0.001), had lower education duration (9.92±3.94 vs. 13.09±3.31 years; p< 0.001), had lower family monthly income (p=0.019), and had longer disease duration (8.25±5.88 vs. 6.74±5.72 years; p=0.001). No significant difference was determined between the two groups regarding gender, living place, and smoking and alcohol consumption.
In conclusion, more than half of the patients had CI and the affecting factors were age, education and income level, and disease duration.
Disclosure:
Serkan Ozakbas: nothing to disclose
Recai Turkoglu: nothing to disclose
Yusuf Tamam: nothing to disclose
Murat Terzi: nothing to disclose
Ozlem Taskapilioglu: nothing to disclose
Canan Cucesan: nothing to disclose
Hatice Limoncu: nothing to disclose
Mehmet Gencer: nothing to disclose
Esref Akil: nothing to disclose
Sedat Sen: nothing to disclose
Mine Hayriye Sorgun: nothing to disclose
Omer Faruk Turan: nothing to disclose
Pinar Yigit: nothing to disclose
Nevin Turkes: nothing to disclose

Abstract: P886

Type: Poster

Abstract Category: Clinical aspects of MS - 5 Epidemiology

Cognitive impairment (CI) is present in 40%-65% of the people with multiple sclerosis (pwMS) and this affects their quality of life. This cross-sectional multicentre study aimed to evaluate the frequency of CI in Turkey for the first time in relapsing-remitting MS patients. Moreover, factors affecting the presence of CI were also evaluated.
Patients between 18 and 55 years of age diagnosed with relapsing-remitting MS according to the 2005 McDonald criteria were included. Number of patients included from 12 geographical regions of Turkey was determined according to the population data of the Turkish Statistical Institute. Patients who had neurological disorders other than MS, those with a previous head trauma, alcohol/drug dependence or mental retardation, and pregnant/lactating women were excluded. MS-related CI was assessed using the Brief Repeatable Neuropsychological Battery (BRB-N), which includes 5 subtests: the Selective Reminding Test to assess verbal memory; the 10/36 Spatial Recall Test (10/36) to assess visual memory; the Symbol Digit Modalities Test to assess attention, visual precision search, and executive functions; the Paced Auditory Serial Addition Task 3 seconds to assess the maintenance of attention; and the Word List Generation to assess associative verbal fluency.
The analysis included 487 MS patients and 245 healthy controls. The cut-off value for CI was determined as -1SD (standard deviation) of the mean value in at least 2 subtests of the BRB-N test of the healthy subjects. Accordingly, the frequency of CI in the MS patients was found as 53.7% (n=248). Comparison of the characteristics of the MS patients with and without CI revealed that those with CI were older (37.32±9.31 vs. 32.08±8.46 years; p< 0.001), had lower education duration (9.92±3.94 vs. 13.09±3.31 years; p< 0.001), had lower family monthly income (p=0.019), and had longer disease duration (8.25±5.88 vs. 6.74±5.72 years; p=0.001). No significant difference was determined between the two groups regarding gender, living place, and smoking and alcohol consumption.
In conclusion, more than half of the patients had CI and the affecting factors were age, education and income level, and disease duration.
Disclosure:
Serkan Ozakbas: nothing to disclose
Recai Turkoglu: nothing to disclose
Yusuf Tamam: nothing to disclose
Murat Terzi: nothing to disclose
Ozlem Taskapilioglu: nothing to disclose
Canan Cucesan: nothing to disclose
Hatice Limoncu: nothing to disclose
Mehmet Gencer: nothing to disclose
Esref Akil: nothing to disclose
Sedat Sen: nothing to disclose
Mine Hayriye Sorgun: nothing to disclose
Omer Faruk Turan: nothing to disclose
Pinar Yigit: nothing to disclose
Nevin Turkes: nothing to disclose

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies